Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Fezolinetant is a selective neurokinin 3 receptor (NK3R) antagonist that blocks neurokinin B signaling in the brain to treat moderate to severe vasomotor symptoms associated with menopause. Clinical trials demonstrate significant reduction in hot flash frequency and severity at doses of 30-45 mg daily.
Reported Benefits (Provisional)
Origin & History
The Fezok Nut is derived from a tree native to the highland forests of East-Central Africa, specifically Uganda, Rwanda, and the Democratic Republic of Congo. Thriving in volcanic soils and high humidity, this nutrient-dense nut is traditionally valued for its energy-boosting and restorative properties in functional nutrition.
Research Narrative (Provisional)
Preliminary research, including in vitro and animal studies, suggests the Fezok Nut's rich profile of fatty acids, tocotrienols, and plant sterols contributes to its traditional uses for energy, fertility, and recovery. Studies are exploring its metabolic, cognitive, and hormonal support mechanisms.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Fatty Acids: Oleic acid, Palmitoleic acid - Vitamins: Tocotrienols (Vitamin E complex), B-complex vitamins - Minerals: Selenium, Magnesium - Phytochemicals: Plant sterols, Catechins, Lignans
Reported Mechanism (Provisional)
Fezolinetant functions as a selective antagonist of neurokinin 3 receptors (NK3R) in the hypothalamus, blocking the action of neurokinin B. This mechanism reduces hypothalamic thermoregulatory dysfunction that causes vasomotor symptoms like hot flashes and night sweats during menopause.
Clinical Narrative (Provisional)
Phase 3 clinical trials including SKYLIGHT 2 demonstrated fezolinetant's efficacy in reducing vasomotor symptoms compared to placebo. A meta-analysis of 5 trials with 3,295 patients (mean age 54.4 years) showed significant reductions in hot flash frequency: 30 mg daily achieved MD = -0.32 (P=0.001) and 45 mg daily achieved MD = -0.49 (P < 0.00001) versus placebo. Benefits were observed from week 1 and sustained through 52 weeks of treatment. Long-term safety was confirmed in a 52-week study involving 1,831 patients.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.